| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f254b1d63391945d4b410d82149620c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6f1de52cd25eb5bab4c74abe5a7bea9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y111-01007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2207-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y111-02002 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y111-02002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-0065
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-34 |
| filingDate |
2019-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f37cbb28e65c9c9ab1b0e722324cb892
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b672892fa898a981a9515c2f72aa5f62 |
| publicationDate |
2020-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020014493-A1 |
| titleOfInvention |
Haloperoxidase compositions and uses thereof |
| abstract |
A method of treating at least one of septicemia, endotoxemia or a bacterial infection in a subject can include administering to the subject a composition containing a therapeutically effective amount of a haloperoxidase. The haloperoxidase can be myeloperoxidase or eosinophil peroxidase. The haloperoxidase can inhibit lipopolysaccharide or Lipid A activity in the subject; as a non-limiting example, the haloperoxidase is not engaged in active haloperoxidase activity, but available for LPS or Lipid A binding and inhibition. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114480226-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114480226-B |
| priorityDate |
2018-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |